Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CDC Loses Faith In AstraZeneca's Nasal Spray Flu Vaccine

Executive Summary

The US Centers for Disease Control and Prevention has decided not to recommend AstraZeneca PLC's nasal spray flu vaccine FluMist Quadrivalent (known as Fluenz Tetra in Europe) for the upcoming flu season owing to lack of efficacy. AstraZeneca said it would take an $80m write-down on stocks in the second quarter as a result.


Related Content

Europe Set To Get Live Pandemic Bird Flu Vaccine Protection


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts